Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Apellis Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Apellis Pharmaceuticals serves clients worldwide.
Website: apellis.com



Growth: Bad revenue growth rate -2.9%, there is slowdown compared to average historical growth rates 130.9%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -23.6%. On average the margin is decreasing steadily. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.11 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 18.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 19.7% higher than minimum and 79.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 5.1x by EV / Sales multiple , the company can be >100% undervalued

Insiders: For the last 3 months insiders sold company shares on $3.4 mln (-0.158% of cap.)

Key Financials (Download financials)

Ticker: APLS
Share price, USD:  (-2.5%)19.59
year average price 27.07  


year start price 39.75 2024-07-27

max close price 41.05 2024-09-06

min close price 16.36 2025-05-15

current price 19.59 2025-07-26
Common stocks: 107 196 299

Dividend Yield:  0.0%
EV / Sales: 2.3x
Margin (EBITDA LTM / Revenue): -23.6%
Fundamental value created in LTM:
Market Cap ($m): 2 100
Net Debt ($m): -305
EV (Enterprise Value): 1 795
Price to Book: 8.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-07-02zacks.com

Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli

2025-05-08zacks.com

Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down

2025-04-02zacks.com

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

2025-03-05seekingalpha.com

Apellis Pharmaceuticals: A Mixed Bag

2025-03-02seekingalpha.com

Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript

2025-02-28zacks.com

Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates

2025-02-28globenewswire.com

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

2025-02-21zacks.com

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2025-02-20globenewswire.com

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

2025-01-19accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Shareholders to Learn More About the Investigation
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol APLS APLS APLS APLS APLS APLS APLS APLS APLS
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-05 2024-08-01 2024-05-07 2024-02-27 2023-11-01 2023-07-31 2023-05-04 2023-02-21 2022-11-07
acceptedDate 2024-11-05 06:57:32 2024-08-01 07:02:24 2024-05-07 07:02:51 2024-02-27 07:01:54 2023-11-01 07:02:15 2023-07-31 16:07:17 2023-05-04 16:02:25 2023-02-21 16:09:51 2022-11-07 16:13:20
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 197M 200M 172M 146M 99M 95M 45M 23M 22M
costOfRevenue 34M 24M 21M 20M 22M 8M 8M 3M 1M
grossProfit 163M 176M 152M 126M 77M 87M 37M 20M 21M
grossProfitRatio 0.83 0.882 0.88 0.864 0.774 0.912 0.826 0.871 0.937
researchAndDevelopmentExpenses 89M 78M 85M 69M 79M 96M 110M 99M 95M
generalAndAdministrativeExpenses 0 0 0 142M 146M 111M 102M 84M 78M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 122M 128M 129M 142M 146M 111M 102M 84M 78M
otherExpenses 0 24 000 -499 000 219 000 -603 000 -63 000 -277 000 -246 000 0
operatingExpenses 211M 206M 214M 211M 225M 207M 212M 184M 174M
costAndExpenses 244M 229M 234M 231M 247M 215M 220M 187M 175M
interestIncome 3M 3M 3M 5M 5M 6M 5M 5M 3M
interestExpense 13M 9M 7M 7M -7M 7M 8M 8M 8M
depreciationAndAmortization 621 000 449 000 444 000 43 812 405 000 410 000 6M 5M 3M
ebitda -44M -28M -62M -84M -148M -115M -170M -159M -150M
ebitdaratio -0.223 -0.145 -0.358 -0.574 -1.495 -1.206 -3.781 -7.029 -6.786
operatingIncome -47M -29M -62M -85M -148M -120M -175M -164M -153M
operatingIncomeRatio -0.24 -0.147 -0.36 -0.577 -1.495 -1.268 -3.904 -7.239 -6.934
totalOtherIncomeExpensesNet -10M -8M -4M -3M 8M -63 000 -2M -3M -38M
incomeBeforeTax -57M -38M -66M -87M -140M -122M -177M -167M -191M
incomeBeforeTaxRatio -0.289 -0.188 -0.384 -0.595 -1.412 -1.283 -3.958 -7.389 -8.652
incomeTaxExpense 592 000 114 000 170 000 1M 233 000 194 000 282 000 -1M 446 000
netIncome -57M -38M -66M -89M -140M -122M -178M -166M -191M
netIncomeRatio -0.292 -0.189 -0.385 -0.605 -1.414 -1.285 -3.964 -7.324 -8.672
eps -0.46 -0.3 -0.54 -0.73 -1.17 -1.02 -1.56 -1.52 -1.75
epsdiluted -0.46 -0.3 -0.54 -0.73 -1.17 -1.02 -1.56 -1.52 -1.75
weightedAverageShsOut 124M 124M 123M 121M 120M 119M 114M 109M 109M
weightedAverageShsOutDil 124M 124M 123M 121M 120M 119M 114M 109M 109M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol APLS APLS APLS APLS APLS APLS APLS APLS APLS
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-05 2024-08-01 2024-05-07 2024-02-27 2023-11-01 2023-07-31 2023-05-04 2023-02-21 2022-11-07
acceptedDate 2024-11-05 06:57:32 2024-08-01 07:02:24 2024-05-07 07:02:51 2024-02-27 07:01:54 2023-11-01 07:02:15 2023-07-31 16:07:17 2023-05-04 16:02:25 2023-02-21 16:09:51 2022-11-07 16:13:20
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 397M 361M 327M 352M 452M 616M 765M 552M 584M
shortTermInvestments 0 8M 8M 4M 13M 9M 0 0 124M
cashAndShortTermInvestments 397M 361M 327M 352M 452M 616M 765M 552M 709M
netReceivables 284M 309M 268M 206M 187M 111M 32M 8M 8M
inventory 121M 153M 161M 146M 99M 103M 85M 86M 60M
otherCurrentAssets 32M 37M 55M 61M 13M 27M 34M 37M 24M
totalCurrentAssets 834M 860M 811M 766M 797M 893M 954M 720M 832M
propertyPlantEquipmentNet 20M 20M 19M 21M 20M 22M 24M 25M 25M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 48M 24M 1M 1M 1M 827 000 793 000 16M 16M
totalNonCurrentAssets 68M 45M 21M 22M 21M 23M 25M 41M 41M
otherAssets 0 1 1 0 0 0 0 0 0
totalAssets 902M 904M 832M 789M 818M 916M 979M 760M 873M
accountPayables 43M 38M 27M 38M 18M 28M 31M 37M 14M
shortTermDebt 14M 12M 84M 6M 6M 6M 6M 6M 5M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 2M 2M 4M 0 117M 98M 0 0 0
otherCurrentLiabilities 133M 117M 101M 204M 45M 44M 101M 125M 96M
totalCurrentLiabilities 191M 169M 215M 248M 186M 175M 139M 168M 115M
longTermDebt 464M 468M 338M 93M 104M 105M 106M 107M 108M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 10M 3M 12M 254M 296M 290M 322M 316M 431M
totalNonCurrentLiabilities 473M 471M 350M 347M 400M 395M 428M 423M 450M
otherLiabilities 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 18M 17M 10M 11M 17M 18M 19M 20M 21M
totalLiabilities 665M 640M 565M 594M 586M 570M 567M 590M 565M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 12 000 12 000 12 000 12 000 12 000 12 000 12 000 11 000 11 000
retainedEarnings -2 999M -2 942M -2 904M -2 837M -2 749M -2 609M -2 487M -2 309M -2 143M
accumulatedOtherComprehensiveIncomeLoss -3M -3M -4M -4M -1M -796 000 -775 000 -875 000 -3M
othertotalStockholdersEquity 3 239M 3 209M 3 174M 3 036M 2 982M 2 955M 2 900M 2 480M 2 453M
totalStockholdersEquity 237M 264M 267M 195M 232M 345M 412M 170M 307M
totalEquity 237M 264M 267M 195M 232M 345M 412M 170M 307M
totalLiabilitiesAndStockholdersEquity 902M 904M 832M 789M 818M 916M 979M 760M 873M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 902M 904M 832M 789M 818M 916M 979M 760M 873M
totalInvestments 0 8M 8M 4M 13M 9M 0 0 124M
totalDebt 470M 475M 431M 111M 110M 111M 112M 113M 113M
netDebt 74M 113M 104M -241M -343M -505M -653M -439M -471M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol APLS APLS APLS APLS APLS APLS APLS APLS APLS
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-05 2024-08-01 2024-05-07 2024-02-27 2023-11-01 2023-07-31 2023-05-04 2023-02-21 2022-11-07
acceptedDate 2024-11-05 06:57:32 2024-08-01 07:02:24 2024-05-07 07:02:51 2024-02-27 07:01:54 2023-11-01 07:02:15 2023-07-31 16:07:17 2023-05-04 16:02:25 2023-02-21 16:09:51 2022-11-07 16:13:20
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -57M -38M -66M -89M -140M -122M -178M -166M -191M
depreciationAndAmortization 457 000 449 000 444 000 490 000 405 000 410 000 399 000 428 000 357 000
deferredIncomeTax 0 0 0 -133 000 133 000 0 0 0 0
stockBasedCompensation 27M 30M 30M 26M 22M 29M 29M 24M 24M
changeInWorkingCapital 63M -6M -103M -43M -57M -64M -36M -4M -28M
accountsReceivables 25M -37M -61M -37M -58M -79M -24M 365 000 -574 000
inventory 9M -15M -15M -48M 5M -18M 144 000 -26M -11M
accountsPayables -1M 11M -11M 20M -10M -4M -6M 23M -7M
otherWorkingCapital 30M 33M -16M 23M 6M 37M 29M -2M -9M
otherNonCashItems 822 000 76M 124M 7M 6M 7M 7M 5M 41M
netCashProvidedByOperatingActivities 34M -8M -133M -98M -169M -150M -178M -141M -154M
investmentsInPropertyPlantAndEquipment 0 -90 000 -293 000 -95 000 -47 000 -372 000 -259 000 -851 000 -196 000
acquisitionsNet 0 0 0 99 000 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 332M 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 125M 125M
otherInvestingActivites 0 0 0 99 000 0 0 0 -332M 0
netCashUsedForInvestingActivites 0 -90 000 -293 000 4000 -47 000 -372 000 -259 000 124M 125M
debtRepayment 0 0 -99M -25M 0 -25M 0 0 0
commonStockIssued -15M -99M 9M 27M 6M 26M 384M -380M 0
commonStockRepurchased 3M 0 -28 000 -2000 -11 000 -28 000 0 4M 0
dividendsPaid 0 0 0 -2M 0 -2M 0 0 0
otherFinancingActivites 3M 42M -28 000 -4M -11 000 2M 7M 360M 10M
netCashUsedProvidedByFinancingActivities 3M 42M 108M -4M 6M 2M 391M -16M 10M
effectOfForexChangesOnCash 173 000 342 000 -209 000 584 000 -458 000 -47 000 56 000 187 000 -310 000
netChangeInCash 37M 34M -25M -101M -164M -149M 213M -32M -20M
cashAtEndOfPeriod 398M 361M 327M 352M 454M 617M 766M 553M 585M
cashAtBeginningOfPeriod 361M 327M 352M 454M 617M 766M 553M 585M 606M
operatingCashFlow 34M -8M -133M -98M -169M -150M -178M -141M -154M
capitalExpenditure 0 -90 000 -293 000 -95 000 -47 000 -372 000 -259 000 -851 000 -196 000
freeCashFlow 34M -8M -133M -98M -169M -151M -178M -142M -155M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-05 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-27 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-07-31 ET (fiscal 2023 q2)
2023 q1
2023-05-06 ET (fiscal 2023 q1)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-11-05 12:05 ET
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
2024-10-26 18:00 ET
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
2024-10-22 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
2024-10-16 11:00 ET
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
2024-10-04 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-25 11:00 ET
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
2024-09-20 09:00 ET
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
2024-09-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-29 11:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2024-08-08 11:29 ET
Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
2024-08-08 11:00 ET
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
2024-08-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-01 11:05 ET
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
2024-07-18 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
2024-07-09 11:00 ET
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
2024-06-28 10:57 ET
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
2024-06-10 11:00 ET
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
2024-06-05 11:00 ET
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-24 14:00 ET
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
2024-05-14 12:00 ET
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
2024-05-07 11:05 ET
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
2024-05-06 11:00 ET
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
2024-05-01 11:00 ET
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2024-04-26 11:15 ET
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
2024-04-23 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
2024-04-04 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-01 11:00 ET
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
2024-03-11 11:00 ET
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
2024-03-06 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-27 12:05 ET
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-26 12:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2024-02-20 12:00 ET
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
2024-02-06 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-26 12:06 ET
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
2024-01-08 14:00 ET
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
2024-01-05 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-02 12:00 ET
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-28 12:00 ET
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
2023-12-14 12:00 ET
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
2023-12-11 12:00 ET
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
2023-12-06 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-21 12:00 ET
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
2023-11-06 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-04 17:37 ET
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
2023-11-01 11:05 ET
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
2023-10-25 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
2023-10-20 12:00 ET
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
2023-10-17 11:00 ET
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
2023-10-05 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-05 11:00 ET
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
2023-10-02 11:00 ET
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
2023-09-25 11:30 ET
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
2023-09-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-30 11:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2023-08-29 10:58 ET
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
2023-08-22 20:43 ET
Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
2023-08-04 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-07-31 11:00 ET
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
2023-07-30 17:00 ET
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)
2023-07-29 18:52 ET
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
2023-07-24 13:00 ET
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
2023-07-10 11:00 ET
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
2023-07-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-07 11:00 ET
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-25 11:00 ET
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
2023-05-05 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-04 20:05 ET
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
2023-05-03 11:00 ET
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
2023-04-27 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
2023-04-23 22:05 ET
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
2023-04-21 11:00 ET
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
2023-04-17 11:00 ET
Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
2023-04-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-06 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-01 12:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2023-02-27 22:19 ET
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
2023-02-23 02:48 ET
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
2023-02-22 12:22 ET
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2023-02-21 21:13 ET
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-17 21:06 ET
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
2023-02-13 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-06 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-05 12:00 ET
Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
2023-01-03 12:00 ET
Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-16 12:00 ET
Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
2022-12-07 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-22 21:05 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2022-11-18 12:00 ET
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
2022-11-07 21:05 ET
Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
2022-11-04 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-03 20:01 ET
Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)
2022-11-03 13:05 ET
Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting
2022-10-31 20:05 ET
Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results
2022-10-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-09-30 21:30 ET
Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
2022-09-30 11:00 ET
Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting
2022-09-12 20:05 ET
Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference
2022-09-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-09-01 11:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2022-08-24 12:00 ET
Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)
2022-08-08 20:05 ET
Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
2022-08-04 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-08-01 20:05 ET
Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial Results
2022-07-27 11:00 ET
Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
2022-07-19 11:00 ET
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy (GA)
2022-07-14 14:01 ET
Apellis Announces Five Oral Presentations in Geographic Atrophy (GA) Highlighted at the ASRS Annual Scientific Meeting
2022-07-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-22 11:00 ET
Apellis Expands R&D Collaboration with Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain
2022-06-10 07:00 ET
Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress
2022-06-07 11:00 ET
Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
2022-06-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-01 20:05 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2022-06-01 11:00 ET
Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy
2022-05-12 15:05 ET
Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
2022-05-06 20:23 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-05-05 20:05 ET
Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference
2022-05-04 20:05 ET
Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results
2022-05-03 11:00 ET
Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company
2022-05-02 19:30 ET
Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
2022-04-26 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results
2022-04-21 11:00 ET
Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)
2022-04-04 11:00 ET
Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
2022-03-28 20:01 ET
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
2022-03-24 11:00 ET
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2022-03-23 20:02 ET
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
2022-03-16 11:00 ET
Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
2022-03-02 12:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2022-02-28 21:05 ET
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-22 12:00 ET
Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results
2022-01-06 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-01-03 12:00 ET
Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-15 12:20 ET
Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH
2021-12-15 12:00 ET
Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH
2021-12-13 16:45 ET
Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population
2021-11-29 12:00 ET
Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
2021-11-18 21:01 ET
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
2021-11-16 12:00 ET
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2021-11-15 21:01 ET
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
2021-11-12 12:00 ET
Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback
2021-11-10 12:00 ET
Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting
2021-11-08 21:01 ET
Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results
2021-11-04 13:17 ET
Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting
2021-11-03 11:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2021-11-01 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on November 8, 2021 to Discuss Third Quarter 2021 Financial Results
2021-10-15 11:36 ET
Aspaveli® (pegcetacoplan) receives positive CHMP opinion for treatment of PNH
2021-10-15 11:17 ET
Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH
2021-10-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-09-30 15:49 ET
Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting
2021-09-20 11:00 ET
Apellis Pharmaceuticals to Present at the 2021 Cantor Virtual Global Healthcare Conference
2021-09-09 20:05 ET
Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
2021-09-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-09-03 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller / Chief Accounting Officer
2021-08-09 20:01 ET
Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results
2021-08-06 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-07-29 11:00 ET
Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results
2021-07-26 11:00 ET
Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
2021-07-08 02:06 ET
Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
2021-07-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-06-30 20:15 ET
Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases
2021-06-23 11:00 ET
Apellis Pharmaceuticals to Host R&D Day on June 30, 2021
2021-06-03 11:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2021-06-01 14:02 ET
Acuamark Diagnostics Welcomes Dr. Cedric Francois To Its Board of Directors
2021-05-25 11:54 ET
Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
2021-05-25 11:00 ET
Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
2021-05-14 22:25 ET
Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
2021-05-12 14:06 ET
Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress
2021-05-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-04-28 20:01 ET
Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results
2021-04-21 11:00 ET
Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021
2021-04-16 16:44 ET
Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2021-04-13 11:00 ET
Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy
2021-03-17 23:39 ET
The NEJM publishes phase 3 PEGASUS study results comparing pegcetacoplan to eculizumab for PNH
2021-03-17 21:48 ET
Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH
2021-03-10 14:15 ET
Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy
2021-03-05 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-03-04 21:05 ET
Apellis Provides Update on APL-9 for Severe COVID-19
2021-02-25 21:01 ET
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-22 13:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2021-02-18 21:05 ET
Apellis Pharmaceuticals to Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on February 25, 2021
2021-02-05 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-01-26 22:00 ET
Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
2021-01-21 12:00 ET
Apellis Pharmaceuticals to Host Investor Event on Geographic Atrophy on January 28, 2021
2021-01-07 11:55 ET
Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
2021-01-05 12:00 ET
Apellis Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-10 11:18 ET
Sobi and Apellis report positive top-line results at 48 weeks from the phase 3 PEGASUS study of pegcetacoplan in PNH
2020-12-10 11:00 ET
Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH
2020-12-07 15:00 ET
Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses and Quality-of-Life Improvements Compared to C5 Inhibitors for PNH
2020-12-04 21:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-11-30 12:00 ET
Apellis Pharmaceuticals to Present at the 2020 Evercore ISI HealthCONx Conference
2020-11-19 11:58 ET
Sobi and Apellis announce first patient dosed in potentially registrational ALS study of pegcetacoplan
2020-11-19 11:45 ET
Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan
2020-11-16 12:00 ET
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
2020-11-13 15:40 ET
Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual
2020-11-11 12:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2020-11-05 12:00 ET
Apellis to Present New Data Supporting the Efficacy and Safety of Pegcetacoplan in PNH at the American Society of Hematology Annual Meeting
2020-11-02 12:00 ET
Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results
2020-10-27 11:00 ET
Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments
2020-10-19 11:00 ET
Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)
2020-10-15 11:00 ET
Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity
2020-10-09 14:14 ET
Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week
2020-10-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-10-05 11:00 ET
Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need
2020-10-03 15:05 ET
Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA)
2020-09-24 20:05 ET
Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit
2020-09-21 20:05 ET
Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020
2020-09-15 11:00 ET
Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH
2020-09-04 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-09-02 11:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2020-08-21 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-08-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-07-31 11:00 ET
Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results
2020-07-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-07-07 11:00 ET
Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
2020-07-02 12:00 ET
Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
2020-06-16 11:00 ET
Apellis Pharmaceuticals to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
2020-06-12 06:30 ET
New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH
2020-06-10 21:34 ET
Apellis Announces Investor Conference Call to Discuss Phase 3 PEGASUS Data to be Presented at the 25th Annual Congress of the European Hematology Association (EHA)
2020-06-05 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-06-04 11:00 ET
Apellis Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
2020-05-29 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-05-28 11:00 ET
Apellis Initiates Phase 1/2 Study of APL-9 in Patients with Severe COVID-19
2020-05-21 11:00 ET
Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)
2020-05-14 14:55 ET
Apellis to Present Pivotal Paroxysmal Nocturnal Hemoglobinuria (PNH) Data at 25th EHA Annual Congress
2020-05-08 11:00 ET
Apellis Pharmaceuticals to Present at the BofA Securities 2020 Health Care Conference
2020-05-07 20:05 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-05-07 11:24 ET
Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
2020-04-29 20:11 ET
Apellis Pharmaceuticals Reports First Quarter 2020 Financial Results
2020-04-28 11:00 ET
Apellis Reports Analysis from Phase 1b Geographic Atrophy Study
2020-04-06 12:00 ET
Paul Fonteyne Joins Apellis Board of Directors
2020-02-27 21:44 ET
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-26 12:00 ET
Apellis Pharmaceuticals to Present at the 40th Annual Cowen Health Care Conference
2020-01-16 21:30 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-01-13 17:10 ET
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
2020-01-09 02:30 ET
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2020-01-07 21:10 ET
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
2020-01-07 12:00 ET
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
2020-01-02 12:00 ET
Apellis Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-11-26 12:00 ET
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2019-11-15 22:30 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-11-08 15:00 ET
Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week
2019-11-07 22:30 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-11-05 12:30 ET
Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results
2019-10-11 20:01 ET
Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019
2019-10-04 21:30 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-09-27 21:30 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-09-26 12:00 ET
Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
2019-09-18 12:00 ET
Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration
2019-09-16 21:00 ET
Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes
2019-09-12 12:22 ET
Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes
2019-09-11 20:38 ET
Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
2019-09-09 21:00 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-03-12 22:00 ET
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-03-11 16:01 ET
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
2019-03-07 12:00 ET
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

SEC forms

Show financial reports only

SEC form 10
2025-05-07 11:01 ET
Apellis Pharmaceuticals reported for 2025 q1
SEC form 10
2025-05-07 00:00 ET
Apellis Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-28 00:00 ET
Apellis Pharmaceuticals reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Apellis Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Apellis Pharmaceuticals published news for 2024 q4
SEC form 10
2024-11-05 06:57 ET
Apellis Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-01 07:02 ET
Apellis Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Apellis Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-07 07:02 ET
Apellis Pharmaceuticals reported for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Apellis Pharmaceuticals published news for 2024 q1
SEC form 8
2024-02-27 07:30 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-27 07:30 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-27 07:01 ET
Apellis Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-01 07:02 ET
Apellis Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
Apellis Pharmaceuticals published news for 2023 q3
SEC form 8
2023-10-05 00:00 ET
Apellis Pharmaceuticals published news for 2023 q3
SEC form 10
2023-07-31 16:07 ET
Apellis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-31 08:03 ET
Apellis Pharmaceuticals reported for 2023 q2
SEC form 10
2023-07-31 00:00 ET
Apellis Pharmaceuticals published news for 2023 q2
SEC form 8
2023-07-31 00:00 ET
Apellis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-17 16:14 ET
Apellis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-01 16:10 ET
Apellis Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Apellis Pharmaceuticals published news for 2023 q1
SEC form 10
2023-02-21 00:00 ET
Apellis Pharmaceuticals reported for 2022 q4
SEC form 10
2022-11-07 00:00 ET
Apellis Pharmaceuticals reported for 2022 q3
SEC form 10
2022-08-08 00:00 ET
Apellis Pharmaceuticals reported for 2022 q2
SEC form 10
2022-05-04 00:00 ET
Apellis Pharmaceuticals reported for 2022 q1
SEC form 10
2022-02-28 00:00 ET
Apellis Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Apellis Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-08 00:00 ET
Apellis Pharmaceuticals published news for 2021 q3
SEC form 10
2021-08-09 00:00 ET
Apellis Pharmaceuticals published news for 2021 q2
SEC form 10
2021-04-28 00:00 ET
Apellis Pharmaceuticals published news for 2021 q1